US Edition
Published • loading... • Updated
Amgen’s lung cancer drug tarlatamab wins China approval - Regional Media News
Summary by regionalmedianews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amgen’s lung cancer drug tarlatamab wins China approval - Regional Media News
SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat. The drug is a targeted immunotherapy for adults in the extensive-stage of hard-to-treat small cell lung cancer that has worsened despite chemotherapy. The U.S. drugmaker sells tarlatamab in its home market under the name I…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
